17 results
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
to £4.3 million for the three months ended June 30, 2022, following agreement with Genentech in February 2023 to wind down the Phase I trial under our … decreased following agreement in February 2023 to wind down the Phase I trial under our collaboration.
Research and Development Expenses
Six Months Ended
6-K
EX-99.1
IMCR
Immunocore Holdings plc
10 May 23
Current report (foreign)
7:27am
the wind-down costs of the IMC-C103C Phase 1 clinical trial. The Group is eligible to receive development and commercial milestone payments plus
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
for the three months ended September 30, 2022, following agreement with Genentech in February 2023 to wind down the Phase 1 clinical trial under … of £3.7 million of costs related to our IMC-C103C program following agreement with Genentech in February 2023 to wind down the Phase 1 clinical trial
6-K
EX-99.1
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
equal share of the wind-down costs of the IMC-C103C Phase 1 clinical trial.
Eli Lilly Collaboration
During the three and nine months ended September 30
6-K
EX-99.1
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
share of the wind-down costs of the IMC-C103C Phase 1 clinical trial.
Eli Lilly Collaboration
During the three and six months ended June 30, 2023
6-K
EX-99.2
9v6 r13mrpo4wvb
10 May 23
Current report (foreign)
7:27am
10-Q
3medpdmjyvo ntq
8 May 24
Quarterly report
7:00am
DRS/A
EX-10.9
nidaf5kk
22 Dec 20
Draft registration statement (amended)
12:00am
F-1
EX-10.10
13i0 aekq
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.7
9ik7cmhsnqq 1klyo
22 Dec 20
Draft registration statement (amended)
12:00am
F-1
EX-10.8
eqra3qk le
15 Jan 21
Registration statement (foreign)
4:57pm
F-1
EX-10.6
sn35m blvybmkb
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.5
b68 uvjtl8pqp
22 Dec 20
Draft registration statement (amended)
12:00am
10-K
qhbxnhty0 766yme
28 Feb 24
Annual report
7:33am
F-1
EX-10.7
8h3ax2ahla
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.6
clan7cjwf 35nd0atq33
22 Dec 20
Draft registration statement (amended)
12:00am
6-K
EX-99.4
15vm7vqgg3h3cfxi8
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
- Prev
- 1
- Next